Basit öğe kaydını göster

dc.contributor.authorIsbir, Turgay
dc.contributor.authorAydogan, Hülya
dc.contributor.authorTekeli, Atike
dc.contributor.authorKucukhuseyin, Ozlem
dc.date.accessioned2021-03-04T13:34:12Z
dc.date.available2021-03-04T13:34:12Z
dc.date.issued2012
dc.identifier.citationAydogan H., Kucukhuseyin O., Tekeli A., Isbir T., "Associations of Receptor for Advanced Glycation End Products -374 T/A and Gly82 Ser and Peroxisome Proliferator-Activated Receptor Gamma Pro12Ala Polymorphisms in Turkish Coronary Artery Disease Patients", GENETIC TESTING AND MOLECULAR BIOMARKERS, cilt.16, sa.2, ss.134-137, 2012
dc.identifier.issn1945-0265
dc.identifier.othervv_1032021
dc.identifier.otherav_7d0fdac9-f537-4a0f-838a-2568eafbcf25
dc.identifier.urihttp://hdl.handle.net/20.500.12627/85491
dc.identifier.urihttps://doi.org/10.1089/gtmb.2011.0077
dc.description.abstractAim: The aim of the present study was to investigate the individual and combined effects of receptor for advanced glycation end products (RAGE) -374T/A, RAGE Gly82Ser, and peroxisome proliferator-activated receptor gamma (PPAR-gamma) Pro12Ala polymorphisms on the development of coronary artery disease (CAD). Materials and Methods: This study was carried out in 87 patients with CAD and 52 CAD-free healthy controls. Polymerase chain reaction, restriction fragment length polymorphism, and agarose gel electrophoresis techniques were used to determine RAGE -374T/A, RAGE Gly82 Ser, and PPAR-gamma Pro12 Ala. Results: Individual allele and genotype frequencies of RAGE -374T/A, RAGE Gly82Ser, and PPAR-gamma Pro12Ala polymorphisms were not significantly different between study groups. However, compared with the control group, wild-type T allele frequency was found to be higher in patients with diabetes (p = 0.009). To investigate the combined effects of RAGE and PPAR polymorphisms, haplotype analysis was elevated and there was no statistical difference between the haplotypes of RAGE Gly82Ser with RAGE-374T/A or PPAR Pro12Ala. However, the frequency of RAGE-374T/PPAR12Ala haplotype was found to be higher in both the patient group (p = 0.024) and in patients without diabetes (p = 0.037). Conclusion: The results of the present study demonstrated that possessing the A allele of RAGE -374T/A polymorphism by diabetic CAD patients and possessing the-374T/A1a12 haplotype of RAGE -3741/A and PPAR-gamma Pro12 Ala polymorphisms by the patients group were the most important risk factors for CAD.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectTemel Bilimler
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Genetik
dc.subjectGENETİK VE HAYAT
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.titleAssociations of Receptor for Advanced Glycation End Products -374 T/A and Gly82 Ser and Peroxisome Proliferator-Activated Receptor Gamma Pro12Ala Polymorphisms in Turkish Coronary Artery Disease Patients
dc.typeMakale
dc.relation.journalGENETIC TESTING AND MOLECULAR BIOMARKERS
dc.contributor.departmentMarmara Üniversitesi , ,
dc.identifier.volume16
dc.identifier.issue2
dc.identifier.startpage134
dc.identifier.endpage137
dc.contributor.firstauthorID71067


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster